HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beaulieu, S. Articles by Mankoff, D. A. Search for Related Content PubMed PubMed Citation Articles by Beaulieu, S. Articles by Mankoff, D. A.

SUV Varies with Time After Injection in ¹⁸F-FDG PET of Breast Cancer: Characterization and Method to Adjust for Time Differences

Division of Nuclear Medicine, University of Washington Medical Center, Seattle, Washington

The purpose of this study was to measure how ¹⁸F-FDG PET standardized uptake values (SUVs) change over time in breast cancer and to examine the feasibility of a method to adjust for modest variations in the time of uptake measurement experienced in clinical practice. Methods:¹⁸F-FDG PET was performed as 60-min dynamic imaging with an additional image acquired at 75 min after injection. For 20 newly diagnosed, untreated, locally advanced breast cancer patients, both the maximum SUV and the average SUV within the lesion were calculated with and without correction for blood glucose concentration. A linear regression analysis of the portion of the time–activity curves starting at 27 min after injection was used to estimate the rate of SUV change per minute during the interval from 27 to 75 min. The rate of SUV change with time was compared with the instantaneous SUV obtained at different times from 27 to 75 min. Results: In untreated breast cancer, ¹⁸F-FDG SUV values changed approximately linearly after 27 min at a rate ranging from -0.02 to 0.15 per minute. In addition, the rate of SUV change was linearly correlated with the instantaneous SUV measured at different times after injection (r² ranged from 0.82 to 0.94; P < 0.001). Using this information, an empirical linear model of SUV variation with time from injection to uptake measurement was formulated. The comparison method was then applied prospectively to a second set of 20 locally advanced breast cancer lesions not included in the initial analysis. The average percent error using the method to adjust for time differences was 8% and 5% for maximum SUVs and average SUVs ranging from 2 to 12. Conclusion: In untreated breast cancer, the SUV at any time point approximately predicts the rate of change of SUV over time. A comparison method based on this finding appears feasible and may improve the usefulness of the SUV by providing a means of comparing SUV acquired at different times after injection.

Key Words: standardized uptake value • ¹⁸F-FDG • breast cancer • PET

This article has been cited by other articles:

				L. K. Dunnwald, J. R. Gralow, G. K. Ellis, R. B. Livingston, H. M. Linden, J. M. Specht, R. K. Doot, T. J. Lawton, W. E. Barlow, B. F. Kurland, et al. Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer J. Clin. Oncol., September 20, 2008; 26(27): 4449 - 4457. [Abstract] [Full Text] [PDF]

				A. Mavi, M. Urhan, J. Q. Yu, H. Zhuang, M. Houseni, T. F. Cermik, D. Thiruvenkatasamy, B. Czerniecki, M. Schnall, and A. Alavi Dual Time Point 18F-FDG PET Imaging Detects Breast Cancer with High Sensitivity and Correlates Well with Histologic Subtypes J. Nucl. Med., September 1, 2006; 47(9): 1440 - 1446. [Abstract] [Full Text] [PDF]

				L. K. Shankar, J. M. Hoffman, S. Bacharach, M. M. Graham, J. Karp, A. A. Lammertsma, S. Larson, D. A. Mankoff, B. A. Siegel, A. Van den Abbeele, et al. Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials J. Nucl. Med., June 1, 2006; 47(6): 1059 - 1066. [Full Text] [PDF]

				B. J. Lopresti, W. E. Klunk, C. A. Mathis, J. A. Hoge, S. K. Ziolko, X. Lu, C. C. Meltzer, K. Schimmel, N. D. Tsopelas, S. T. DeKosky, et al. Simplified Quantification of Pittsburgh Compound B Amyloid Imaging PET Studies: A Comparative Analysis J. Nucl. Med., December 1, 2005; 46(12): 1959 - 1972. [Abstract] [Full Text] [PDF]

				R. Kumar, V. A. Loving, A. Chauhan, H. Zhuang, S. Mitchell, and A. Alavi Potential of Dual-Time-Point Imaging to Improve Breast Cancer Diagnosis with 18F-FDG PET J. Nucl. Med., November 1, 2005; 46(11): 1819 - 1824. [Abstract] [Full Text] [PDF]

				J. R. Tseng, M. Dandekar, M. Subbarayan, Z. Cheng, J. M. Park, S. Louie, and S. S. Gambhir Reproducibility of 3'-Deoxy-3'-18F-Fluorothymidine MicroPET Studies in Tumor Xenografts in Mice J. Nucl. Med., November 1, 2005; 46(11): 1851 - 1857. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				Y.-Y. Yau, W.-S. Chan, Y.-M. Tam, P. Vernon, S. Wong, M. Coel, and S. K.-F. Chu Application of Intravenous Contrast in PET/CT: Does It Really Introduce Significant Attenuation Correction Error? J. Nucl. Med., February 1, 2005; 46(2): 283 - 291. [Abstract] [Full Text] [PDF]

				D. L. Schwartz, J. Rajendran, B. Yueh, M. D. Coltrera, M. LeBlanc, J. Eary, and K. Krohn FDG-PET Prediction of Head and Neck Squamous Cell Cancer Outcomes Arch Otolaryngol Head Neck Surg, December 1, 2004; 130(12): 1361 - 1367. [Abstract] [Full Text] [PDF]

				J. A. Thie Understanding the Standardized Uptake Value, Its Methods, and Implications for Usage J. Nucl. Med., September 1, 2004; 45(9): 1431 - 1434. [Full Text] [PDF]